{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T12:11:19Z","timestamp":1783685479360,"version":"3.55.0"},"reference-count":110,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T00:00:00Z","timestamp":1753747200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Basic to Translational Science"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jacbts.2025.101364","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T22:33:57Z","timestamp":1757543637000},"page":"101364","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Small Interfering RNA Therapy Targeting the Long Noncoding RNA SMILR for Therapeutic Intervention in Coronary Artery Bypass Graft Failure"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1679-4856","authenticated-orcid":false,"given":"Simon D.","family":"Brown","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna L.","family":"Malinowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1423-3449","authenticated-orcid":false,"given":"Andr\u00e9s F.","family":"Correa-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laia Linda","family":"Horcasitas Valencia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee P.","family":"Lucignoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7953-3015","authenticated-orcid":false,"given":"Anna K.","family":"Barton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Clark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0269-4582","authenticated-orcid":false,"given":"Judith C.","family":"Sluimer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott P.","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Rodor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David E.","family":"Newby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1441-5576","authenticated-orcid":false,"given":"Andrew H.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacbts.2025.101364_bib1","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMra1406944","article-title":"Coronary-artery bypass grafting","volume":"374","author":"Alexander","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2025.101364_bib2","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1161\/01.CIR.97.9.916","article-title":"Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention","volume":"97","author":"Motwani","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2025.101364_bib3","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1161\/01.CIR.102.14.1697","article-title":"Direct evidence for cytokine involvement in neointimal hyperplasia","volume":"102","author":"Rectenwald","year":"2000","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2025.101364_bib4","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/cvr\/cvs115","article-title":"Smooth muscle cell phenotypic switching in atherosclerosis","volume":"95","author":"Gomez","year":"2012","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacbts.2025.101364_bib5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1152\/physrev.00041.2003","article-title":"Molecular regulation of vascular smooth muscle cell differentiation in development and disease","volume":"84","author":"Owens","year":"2004","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jacbts.2025.101364_bib6","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/nrcardio.2016.76","article-title":"Vein graft failure: from pathophysiology to clinical outcomes","volume":"13","author":"de Vries","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacbts.2025.101364_bib7","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.jacc.2004.08.064","article-title":"Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery: results from a Department of Veterans Affairs Cooperative Study","volume":"44","author":"Goldman","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2025.101364_bib8","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/0735-1097(96)00206-9","article-title":"Coronary bypass graft fate and patient outcome: angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years","volume":"28","author":"Fitzgibbon","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacbts.2025.101364_bib9","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.athoracsur.2004.07.047","article-title":"Comparison of saphenous vein and internal thoracic artery graft patency by coronary system","volume":"79","author":"Sabik","year":"2005","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacbts.2025.101364_bib10","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/SLA.0b013e318288c38d","article-title":"Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management, and future directions","volume":"257","author":"Harskamp","year":"2013","journal-title":"Ann Surg"},{"key":"10.1016\/j.jacbts.2025.101364_bib11","doi-asserted-by":"crossref","first-page":"2302","DOI":"10.1056\/NEJMoa040982","article-title":"A randomized comparison of radial-artery and saphenous-vein coronary bypass grafts","volume":"351","author":"Desai","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2025.101364_bib12","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.ejcts.2005.01.027","article-title":"Has the in situ right internal thoracic artery been overlooked? An angiographic study of the radial artery, internal thoracic arteries and saphenous vein graft patencies in symptomatic patients","volume":"27","author":"Shah","year":"2005","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jacbts.2025.101364_bib13","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1161\/01.CIR.0000127570.20508.5C","article-title":"Radial artery bypass grafts have an increased occurrence of angiographically severe stenosis and occlusion compared with left internal mammary arteries and saphenous vein grafts","volume":"109","author":"Khot","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2025.101364_bib14","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/CIRCULATIONAHA.113.008193","article-title":"Saphenous vein graft failure after coronary artery bypass surgery: insights from PREVENT IV","volume":"130","author":"Hess","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2025.101364_bib15","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0002-9149(94)90198-8","article-title":"Frequency of repeat coronary bypass or coronary angioplasty after coronary artery bypass surgery using saphenous venous grafts","volume":"73","author":"Weintraub","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacbts.2025.101364_bib16","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/archinte.163.19.2306","article-title":"Peripheral arterial disease: identification and implications","volume":"163","author":"Mohler","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jacbts.2025.101364_bib17","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1161\/01.CIR.0000121743.10146.78","article-title":"Improved survival with radial artery versus vein conduits in coronary bypass surgery with left internal thoracic artery to left anterior descending artery grafting","volume":"109","author":"Zacharias","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2025.101364_bib18","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.ejcts.2005.12.026","article-title":"Serial angiographic follow-up of grafts one year and five years after coronary artery bypass surgery","volume":"29","author":"Cho","year":"2006","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jacbts.2025.101364_bib19","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0022-5223(19)38820-8","article-title":"Long-term (5 to 12 years) serial studies of internal mammary artery and saphenous vein coronary bypass grafts","volume":"89","author":"Lytle","year":"1985","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacbts.2025.101364_bib20","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1161\/CIRCULATIONAHA.107.736215","article-title":"Radial artery versus saphenous vein patency randomized trial: five-year angiographic follow-up","volume":"117","author":"Collins","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2025.101364_bib21","first-page":"I208","article-title":"Comparison of late changes in internal mammary artery and saphenous vein grafts in two consecutive series of patients 10 years after operation","volume":"70","author":"Grondin","year":"1984","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2025.101364_bib22","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1161\/CIR.0000000000000182","article-title":"Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association","volume":"131","author":"Kulik","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2025.101364_bib23","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/0002-8703(92)90716-9","article-title":"Stenting of venous bypass grafts: a new treatment modality for patients who are poor candidates for reintervention","volume":"123","author":"de Scheerder","year":"1992","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacbts.2025.101364_bib24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.amjcard.2016.05.040","article-title":"Angiographic findings and revascularization success in patients with acute myocardial infarction and previous coronary bypass grafting","volume":"118","author":"Blachutzik","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacbts.2025.101364_bib25","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/ejcts\/ezab391","article-title":"Coronary artery bypass surgery in the UK, trends in activity and outcomes from a 15-year complete national series","volume":"61","author":"Ohri","year":"2022","journal-title":"Eur J Cardiothorac Surg"},{"key":"10.1016\/j.jacbts.2025.101364_bib26","article-title":"Long-term clinical outcomes of percutaneous coronary intervention in saphenous vein grafts in a low to middle-income country","volume":"12","author":"Adnan","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.jacbts.2025.101364_bib27","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.hlc.2019.02.008","article-title":"Risk factors and outcomes in redo coronary artery bypass grafting","volume":"29","author":"Gallo","year":"2020","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.jacbts.2025.101364_bib28","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/j.athoracsur.2016.09.097","article-title":"Reoperation for coronary artery bypass grafting surgery: outcomes and considerations for expanding interventional procedures","volume":"103","author":"Maltais","year":"2017","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacbts.2025.101364_bib29","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2147\/vhrm.2006.2.4.477","article-title":"Outcomes of coronary artery bypass graft surgery","volume":"2","author":"Hawkes","year":"2006","journal-title":"Vasc Health Risk Manag"},{"issue":"2","key":"10.1016\/j.jacbts.2025.101364_bib30","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/bph.16409","article-title":"Non-coding RNAs to treat vascular smooth muscle cell dysfunction","volume":"182","author":"Brown","year":"2025","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jacbts.2025.101364_bib31","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1161\/CIRCULATIONAHA.115.021019","article-title":"Smooth muscle enriched long noncoding RNA (SMILR) regulates cell proliferation","volume":"133","author":"Ballantyne","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2025.101364_bib32","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1172\/JCI24838","article-title":"Reversal of experimental pulmonary hypertension by PDGF inhibition","volume":"115","author":"Schermuly","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacbts.2025.101364_bib33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1002\/ddr.21230","article-title":"Nobiletin inhibits PDGF-BB-induced vascular smooth muscle cell proliferation and migration and attenuates neointimal hyperplasia in a rat carotid artery injury model","volume":"75","author":"Guan","year":"2014","journal-title":"Drug Dev Res"},{"key":"10.1016\/j.jacbts.2025.101364_bib34","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.yexcr.2015.06.020","article-title":"Iptakalim inhibits PDGF-BB-induced human airway smooth muscle cells proliferation and migration","volume":"336","author":"Liu","year":"2015","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.jacbts.2025.101364_bib35","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nature09701","article-title":"lncRNAs transactivate STAU1-mediated mRNA decay by duplexing with 3' UTRs via Alu elements","volume":"470","author":"Gong","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.jacbts.2025.101364_bib36","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1161\/CIRCRESAHA.119.314876","article-title":"The human-specific and smooth muscle cell-enriched LncRNA SMILR promotes proliferation by regulating mitotic CENPF mRNA and drives cell-cycle progression which can be targeted to limit vascular remodeling","volume":"125","author":"Mahmoud","year":"2019","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2025.101364_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.1006304","article-title":"A perspective on oligonucleotide therapy: Approaches to patient customization","volume":"13","author":"Thakur","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacbts.2025.101364_bib38","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","article-title":"Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates","volume":"26","author":"Foster","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.jacbts.2025.101364_bib39","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.jacbts.2025.101364_bib40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","article-title":"Therapeutic siRNA: state of the art","volume":"5","author":"Hu","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"Pt 1","key":"10.1016\/j.jacbts.2025.101364_bib41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1042\/bj2880093","article-title":"Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation","volume":"288","author":"Southgate","year":"1992","journal-title":"Biochem J"},{"key":"10.1016\/j.jacbts.2025.101364_bib42","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1093\/bioinformatics\/btr509","article-title":"A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data","volume":"27","author":"Li","year":"2011","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jacbts.2025.101364_bib43","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.jacbts.2025.101364_bib44","unstructured":"Alexa A, Rahnenfuhrer J. topGO: Enrichment Analysis for Gene Ontology. 2025. R package version 2.60.1. https:\/\/doi.org\/10.18129\/B9.bioc.topGO"},{"key":"10.1016\/j.jacbts.2025.101364_bib45","doi-asserted-by":"crossref","first-page":"3292","DOI":"10.1038\/s41596-024-01020-z","article-title":"Using clusterProfiler to characterize multiomics data","volume":"19","author":"Xu","year":"2024","journal-title":"Nat Protoc"},{"key":"10.1016\/j.jacbts.2025.101364_bib46","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.jacbts.2025.101364_bib47","first-page":"129","article-title":"miRBase: the microRNA sequence database","volume":"342","author":"Griffiths-Jones","year":"2006","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.jacbts.2025.101364_bib48","doi-asserted-by":"crossref","first-page":"403","DOI":"10.4097\/kjae.2010.59.6.403","article-title":"The optimal concentration of siRNA for gene silencing in primary cultured astrocytes and microglial cells of rats","volume":"59","author":"Ki","year":"2010","journal-title":"Korean J Anesthesiol"},{"key":"10.1016\/j.jacbts.2025.101364_bib49","doi-asserted-by":"crossref","first-page":"6347","DOI":"10.1073\/pnas.1131959100","article-title":"Specificity of short interfering RNA determined through gene expression signatures","volume":"100","author":"Semizarov","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2025.101364_bib50","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.omtn.2022.06.009","article-title":"Chemical optimization of siRNA for safe and efficient silencing of placental sFLT1","volume":"29","author":"Davis","year":"2022","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jacbts.2025.101364_bib51","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","article-title":"The Ki-67 protein: from the known and the unknown","volume":"182","author":"Scholzen","year":"2000","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jacbts.2025.101364_bib52","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jconrel.2019.03.028","article-title":"The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo","volume":"302","author":"Biscans","year":"2019","journal-title":"J Control Release"},{"key":"10.1016\/j.jacbts.2025.101364_bib53","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1093\/nar\/gky1239","article-title":"Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo","volume":"47","author":"Biscans","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jacbts.2025.101364_bib54","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1016\/j.jid.2016.06.626","article-title":"Development of cell-penetrating asymmetric interfering rna targeting connective tissue growth factor","volume":"136","author":"Hwang","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jacbts.2025.101364_bib55","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jconrel.2023.09.001","article-title":"Polyethylenimine (PEI) in gene therapy: current status and clinical applications","volume":"362","author":"Casper","year":"2023","journal-title":"J Control Release"},{"key":"10.1016\/j.jacbts.2025.101364_bib56","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1016\/j.juro.2013.12.011","article-title":"DNA based therapy with diphtheria toxin-A BC-819: a phase 2b marker lesion trial in patients with intermediate risk nonmuscle invasive bladder cancer","volume":"191","author":"Gofrit","year":"2014","journal-title":"J Urol"},{"key":"10.1016\/j.jacbts.2025.101364_bib57","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1158\/1535-7163.MCT-23-0652","article-title":"First-in-human stage III\/IV melanoma clinical trial of immune priming agent IFx-Hu2.0","volume":"23","author":"Markowitz","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jacbts.2025.101364_bib58","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1261\/rna.25706","article-title":"Widespread siRNA \"off-target\" transcript silencing mediated by seed region sequence complementarity","volume":"12","author":"Jackson","year":"2006","journal-title":"RNA"},{"key":"10.1016\/j.jacbts.2025.101364_bib59","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/jmcb\/mjy063","article-title":"Assembly of a parts list of the human mitotic cell cycle machinery","volume":"11","author":"Giotti","year":"2019","journal-title":"J Mol Cell Biol"},{"key":"10.1016\/j.jacbts.2025.101364_bib60","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/75556","article-title":"Gene ontology: tool for the unification of biology. The Gene Ontology Consortium","volume":"25","author":"Ashburner","year":"2000","journal-title":"Nat Genet"},{"key":"10.1016\/j.jacbts.2025.101364_bib61","article-title":"The Gene Ontology knowledgebase in 2023","volume":"224","author":"Aleksander","year":"2023","journal-title":"Genetics"},{"key":"10.1016\/j.jacbts.2025.101364_bib62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/nar\/28.1.27","article-title":"KEGG: Kyoto encyclopedia of genes and genomes","volume":"28","author":"Kanehisa","year":"2000","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jacbts.2025.101364_bib63","doi-asserted-by":"crossref","first-page":"D672","DOI":"10.1093\/nar\/gkae909","article-title":"KEGG: biological systems database as a model of the real world","volume":"53","author":"Kanehisa","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jacbts.2025.101364_bib64","doi-asserted-by":"crossref","first-page":"D672","DOI":"10.1093\/nar\/gkad1025","article-title":"The Reactome Pathway Knowledgebase 2024","volume":"52","author":"Milacic","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jacbts.2025.101364_bib65","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12859-017-1559-2","article-title":"Reactome pathway analysis: a high-performance in-memory approach","volume":"18","author":"Fabregat","year":"2017","journal-title":"BMC Bioinformatics"},{"key":"10.1016\/j.jacbts.2025.101364_bib66","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0950-821X(05)80919-3","article-title":"Winner of the ESVS prize 1990. Smooth muscle cell proliferation in response to injury in an organ culture of human saphenous vein","volume":"5","author":"Angelini","year":"1991","journal-title":"Eur J Vasc Surg"},{"key":"10.1016\/j.jacbts.2025.101364_bib67","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1093\/cvr\/27.11.1961","article-title":"Surgical preparation induces injury and promotes smooth muscle cell proliferation in a culture of human saphenous vein","volume":"27","author":"Soyombo","year":"1993","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.jacbts.2025.101364_bib68","first-page":"1401","article-title":"Intimal proliferation in an organ culture of human saphenous vein","volume":"137","author":"Soyombo","year":"1990","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jacbts.2025.101364_bib69","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/nar\/gkp841","article-title":"Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents","volume":"38","author":"Stein","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jacbts.2025.101364_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.jim.2019.112674","article-title":"Use of GapmeRs for gene expression knockdowns in human primary resting CD4+ T cells","volume":"476","author":"Abewe","year":"2020","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jacbts.2025.101364_bib71","doi-asserted-by":"crossref","first-page":"4635","DOI":"10.1016\/j.bmc.2018.07.033","article-title":"Gymnotic delivery and gene silencing activity of reduction-responsive siRNAs bearing lipophilic disulfide-containing modifications at 2'-position","volume":"26","author":"Gauthier","year":"2018","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.jacbts.2025.101364_bib72","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(04)17275-9","article-title":"Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy","volume":"364","author":"McFadden","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2025.101364_bib73","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.294.19.2446","article-title":"Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial","volume":"294","author":"Alexander","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.jacbts.2025.101364_bib74","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1073\/pnas.92.13.5855","article-title":"A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo","volume":"92","author":"Morishita","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2025.101364_bib75","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1527-3466.2007.00020.x","article-title":"Edifoligide: a transcription factor decoy to modulate smooth muscle cell proliferation in vein bypass","volume":"25","author":"Hoel","year":"2007","journal-title":"Cardiovasc Drug Rev"},{"key":"10.1016\/j.jacbts.2025.101364_bib76","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1067\/mtc.2001.111204","article-title":"Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy","volume":"121","author":"Ehsan","year":"2001","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jacbts.2025.101364_bib77","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1161\/01.CIR.0000013775.02396.93","article-title":"Endothelial healing in vein grafts: proliferative burst unimpaired by genetic therapy of neointimal disease","volume":"105","author":"Ehsan","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2025.101364_bib78","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S0140-6736(99)09405-2","article-title":"Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial","volume":"354","author":"Mann","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2025.101364_bib79","series-title":"Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) II trial","author":"Grube","year":"2001"},{"key":"10.1016\/j.jacbts.2025.101364_bib80","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jvs.2005.12.058","article-title":"Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery","volume":"43","author":"Conte","year":"2006","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.jacbts.2025.101364_bib81","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1161\/01.CIR.0000148139.79580.36","article-title":"One-year coronary bypass graft patency: a randomized comparison between off-pump and on-pump surgery angiographic results of the PRAGUE-4 trial","volume":"110","author":"Widimsky","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2025.101364_bib82","doi-asserted-by":"crossref","first-page":"12988","DOI":"10.1073\/pnas.0704754104","article-title":"Distinct roles of E2F proteins in vascular smooth muscle cell proliferation and intimal hyperplasia","volume":"104","author":"Giangrande","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2025.101364_bib83","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1161\/01.CIR.98.25.2883","article-title":"Restoration of E2F expression rescues vascular endothelial cells from tumor necrosis factor-alpha-induced apoptosis","volume":"98","author":"Spyridopoulos","year":"1998","journal-title":"Circulation"},{"key":"10.1016\/j.jacbts.2025.101364_bib84","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1161\/01.RES.0000082980.94211.3A","article-title":"Engineering the response to vascular injury: divergent effects of deregulated E2F1 expression on vascular smooth muscle cells and endothelial cells result in endothelial recovery and inhibition of neointimal growth","volume":"93","author":"Goukassian","year":"2003","journal-title":"Circ Res"},{"key":"10.1016\/j.jacbts.2025.101364_bib85","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1208760","article-title":"Safety and efficacy of RNAi therapy for transthyretin amyloidosis","volume":"369","author":"Coelho","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2025.101364_bib86","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1186\/s13023-015-0326-6","article-title":"Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study","volume":"10","author":"Suhr","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jacbts.2025.101364_bib87","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2025.101364_bib88","doi-asserted-by":"crossref","first-page":"7777","DOI":"10.1073\/pnas.1406228111","article-title":"RNAi-mediated silencing of hepatic Alas1 effectively prevents and treats the induced acute attacks in acute intermittent porphyria mice","volume":"111","author":"Yasuda","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2025.101364_bib89","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2015.36","article-title":"Preclinical development of a subcutaneous ALAS1 RNAi therapeutic for treatment of hepatic porphyrias using circulating RNA quantification","volume":"4","author":"Chan","year":"2015","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.jacbts.2025.101364_bib90","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMoa1807838","article-title":"Phase 1 trial of an RNA interference therapy for acute intermittent porphyria","volume":"380","author":"Sardh","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2025.101364_bib91","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/cpt.1802","article-title":"Pharmacokinetics and pharmacodynamics of the small interfering ribonucleic acid, givosiran, in patients with acute hepatic porphyria","volume":"108","author":"Agarwal","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jacbts.2025.101364_bib92","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi therapeutic for primary hyperoxaluria type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2025.101364_bib93","doi-asserted-by":"crossref","first-page":"11915","DOI":"10.1073\/pnas.0805434105","article-title":"Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates","volume":"105","author":"Frank-Kamenetsky","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jacbts.2025.101364_bib94","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0140-6736(13)61914-5","article-title":"Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin\/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial","volume":"383","author":"Fitzgerald","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2025.101364_bib95","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A highly durable RNAi therapeutic inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2025.101364_bib96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","article-title":"Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial","volume":"30","author":"Adams","year":"2023","journal-title":"Amyloid"},{"key":"10.1016\/j.jacbts.2025.101364_bib97","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.kint.2022.07.025","article-title":"PHYOX2: a pivotal randomized study of nedosiran in primary hyperoxaluria type 1 or 2","volume":"103","author":"Baum","year":"2023","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacbts.2025.101364_bib98","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1182\/blood.2023021864","article-title":"Fitusiran prophylaxis in people with hemophilia A or B who switched from prior BPA\/CFC prophylaxis: the ATLAS-PPX trial","volume":"143","author":"Kenet","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.jacbts.2025.101364_bib99","doi-asserted-by":"crossref","first-page":"e322","DOI":"10.1016\/S2352-3026(23)00037-6","article-title":"Fitusiran prophylaxis in people with severe haemophilia A or haemophilia B without inhibitors (ATLAS-A\/B): a multicentre, open-label, randomised, phase 3 trial","volume":"10","author":"Srivastava","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jacbts.2025.101364_bib100","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(23)00284-2","article-title":"Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial","volume":"401","author":"Young","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2025.101364_bib101","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa2404143","article-title":"Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia","volume":"391","author":"Ballantyne","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2025.101364_bib102","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa2409368","article-title":"Plozasiran for managing persistent chylomicronemia and pancreatitis risk","volume":"392","author":"Watts","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacbts.2025.101364_bib103","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.1093\/nar\/gkw236","article-title":"The delivery of therapeutic oligonucleotides","volume":"44","author":"Juliano","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jacbts.2025.101364_bib104","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat Biotechnol"},{"issue":"4","key":"10.1016\/j.jacbts.2025.101364_bib105","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.3390\/ijms26041658","article-title":"Clinical proof-of-concept of a non-gene editing technology using miRNA-based shRNA to engineer allogeneic CAR T-cells","volume":"26","author":"Lonez","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jacbts.2025.101364_bib106","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0140-6736(24)02462-0","article-title":"Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial","volume":"405","author":"Ghobadi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jacbts.2025.101364_bib107","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/jocs.13608","article-title":"The effect of storage solutions, gene therapy, and antiproliferative agents on endothelial function and saphenous vein graft patency","volume":"33","author":"Ben Ali","year":"2018","journal-title":"J Card Surg"},{"key":"10.1016\/j.jacbts.2025.101364_bib108","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3233\/CH-131781","article-title":"Heparinized blood better preserves cellular energy charge and vascular functions of intraoperatively stored saphenous vein grafts in comparison to isotonic sodium-chloride-solution","volume":"55","author":"Wilbring","year":"2013","journal-title":"Clin Hemorheol Microcirc"},{"key":"10.1016\/j.jacbts.2025.101364_bib109","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1001\/jamasurg.2014.87","article-title":"Vein graft preservation solutions, patency, and outcomes after coronary artery bypass graft surgery: follow-up from the PREVENT IV randomized clinical trial","volume":"149","author":"Harskamp","year":"2014","journal-title":"JAMA Surg"},{"key":"10.1016\/j.jacbts.2025.101364_bib110","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1093\/eurheartj\/ehae654","volume":"46","author":"Sandner","year":"2025","journal-title":"Eur Heart J"}],"container-title":["JACC: Basic to Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X25003171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2452302X25003171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T19:33:39Z","timestamp":1764012819000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2452302X25003171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":110,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2452302X25003171"],"URL":"https:\/\/doi.org\/10.1016\/j.jacbts.2025.101364","relation":{},"ISSN":["2452-302X"],"issn-type":[{"value":"2452-302X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small Interfering RNA Therapy Targeting the Long Noncoding RNA SMILR for Therapeutic Intervention in Coronary Artery Bypass Graft Failure","name":"articletitle","label":"Article Title"},{"value":"JACC: Basic to Translational Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacbts.2025.101364","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"101364"}}